Typicality: | 0.400 |
Saliency: | 0.352 |
previously | 5 | temporal |
on the market | 3 | location |
for their efficacy against cancer cells | 3 | purpose |
drug → be approved for → other uses | 22 |
drug → be approved for → other indications | 14 |
drug → be approved for → other purposes | 6 |
negative | neutral | positive |
0.066 | 0.605 | 0.329 |
Raw frequency | 42 |
Normalized frequency | 0.352 |
Modifier score | 0.500 |
Perplexity | 17.975 |